Stockreport

Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results

Erasca, Inc.  (ERAS) 
PDF Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, toler [Read more]